von Holst H, Nygren C, Boström K, Collins V P, Fredman P
Department of Neurosurgery, Karclinska Hospital, Stockholm, Sweden.
Acta Neurochir (Wien). 1997;139(2):141-5. doi: 10.1007/BF02747194.
Glioma-associated gangliosides, in particular the expression of foetal gangliosides 3'-isoLM1 and 3'6'-isoLD1, have been investigated in biopsies from 44 patients with astrocytoma grade II, anaplastic astrocytoma, anaplastic oligodendrogliomas, oligodendrogliomas, and glioblastoma multiforme. The total ganglioside content decreased in proportion to the estimated number of tumour cells present in the biopsy. Ganglioside GD3 was increased in 17 of the tumour tissues and in 6 of the surrounding area specimens. In agreement with our previous studies, tumour specimens contained the lactoseries ganglioside 3'-isoLM1 and, as demonstrated for the first time, the disialylated form of the ganglioside, 3'6'-isoLD1. These gangliosides are in normal brain tissue restricted to the developmental period. Most frequent was the expression of ganglioside 3'-isoLM1 which was detected in 92% of the tumour specimens in concentrations varying between just detectable amounts to 13 nmol/g wet weight. In the area surrounding the macroscopic tumour tissue 78% of the specimens expressed 3'-isoLM1 and the values varied between just detectable amounts to 24 nmol/g wet weight. Ganglioside 3'6'-isoLD1 was found in 47% of the tumour biopsies and in only 17% of the specimens taken outside macroscopic tumour tissue. The values varied between non-detectable amounts to 40 nmol/g wet weight of tissue. The expression of 3'-isoLM1 correlated significantly (p < 0.01) to malignancy grade. For 3'6'-isoLD1 a significant (p < 0.05) difference was found between tumour and surrounding tissue. Likewise, 3'6'-isoLD1 correlated significantly (p < 0.05) to malignancy grade. The correlation between 3'-isoLM1 and 3'6'-isoLD1 to malignancy grade and the frequent expression of these gangliosides both in the tumour itself and in its surrounding area should encourage additional studies concerning their biological role in tumour disease.
已对44例患有二级星形细胞瘤、间变性星形细胞瘤、间变性少突胶质细胞瘤、少突胶质细胞瘤和多形性胶质母细胞瘤患者的活检样本中的胶质瘤相关神经节苷脂,特别是胎儿神经节苷脂3'-isoLM1和3'6'-isoLD1的表达情况进行了研究。总神经节苷脂含量与活检样本中估计的肿瘤细胞数量成比例下降。17个肿瘤组织和6个周边区域样本中的神经节苷脂GD3含量增加。与我们之前的研究一致,肿瘤样本中含有乳糖系列神经节苷脂3'-isoLM1,并且首次证实了该神经节苷脂的双唾液酸化形式3'6'-isoLD1。这些神经节苷脂在正常脑组织中仅限于发育阶段表达。最常见的是神经节苷脂3'-isoLM1的表达,在92%的肿瘤样本中检测到,其浓度在刚刚可检测到的量至13 nmol/g湿重之间变化。在宏观肿瘤组织周围区域,78%的样本表达3'-isoLM1,其值在刚刚可检测到的量至24 nmol/g湿重之间变化。神经节苷脂3'6'-isoLD1在47%的肿瘤活检样本中被发现,而在宏观肿瘤组织外采集的样本中仅17%被发现。其值在不可检测到的量至40 nmol/g湿重的组织之间变化。3'-isoLM1的表达与恶性程度显著相关(p < 0.01)。对于3'6'-isoLD1,在肿瘤组织和周围组织之间发现了显著差异(p < 0.05)。同样,3'6'-isoLD1与恶性程度显著相关(p < 0.05)。3'-isoLM1和3'6'-isoLD1与恶性程度之间的相关性以及这些神经节苷脂在肿瘤本身及其周围区域的频繁表达,应促使人们对它们在肿瘤疾病中的生物学作用进行更多研究。